Paclitaxel-loaded poly(Glycolide-co-εcaprolactone)-b-d-α-tocopheryl polyethylene glycol 2000 succinate nanoparticles for lung cancer therapy

International Journal of Nanomedicine

Volumn 8, Issue , 2013, Pages 1947-1957

  Zhao, Tiejun ^a   Chen, Hezhong ^a   Dong, Yuchao ^a   Zhang, Jiajun ^a   Huang, Haidong ^a   Zhu, Ji ^a   Zhang, Wei ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

(PGA co PCL) b TPGS2k; Drug delivery; Lung cancer; Nanoparticles; Paclitaxel

Indexed keywords

AMPHOPHILE; COPOLYMER; COUMARIN; NANOPARTICLE; PACLITAXEL; POLY(GLYCOLIDE CO EPSILON CAPROLACTONE) BETA DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL 2000 SUCCINATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MOUSE; MULTIPLE CYCLE TREATMENT; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; POLYMERIZATION; PROTON NUCLEAR MAGNETIC RESONANCE; RING OPENING; STRUCTURE ANALYSIS; SURFACE PROPERTY; ZETA POTENTIAL;

(PGA-CO-PCL)-B-TPGS2K; DRUG DELIVERY; LUNG CANCER; NANOPARTICLES; PACLITAXEL;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL LINE, TUMOR; CELL SURVIVAL; COUMARINS; DRUG DELIVERY SYSTEMS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NANOPARTICLES; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; POLYESTERS; POLYETHYLENE GLYCOLS; THIAZOLES; VITAMIN E; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84877977837     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S44220     Document Type: Article

References (49)

1. Johnson DH. Treatment strategies for metastatic non small-cell lung cancer. Clin Lung Cancer. 1999;1:34-41.
2. Horeweg N, van Klaveren RJ, Groen HJM, et al. Blinded and uniform cause of death verification in a lung cancer CT screening trial. Lung Cancer. 2012;77:522-525.
3. Kaustubh AJ, Chakkumkal A, Mukesh KK, Tamishraha B, Amulya KP, Ambikanandan RM. Liposomal formulations of etoposide and docetaxel for p53 mediated enhanced cytotoxicity in lung cancer cell lines. Biomaterials. 2012;33:2492-2507.
4. Kim I, Byeon HJ, Kim TH, et al. Doxorubicin-loaded highly porous large PLGA microparticles as a sustained-release inhalation system for the treatment of metastatic lung cancer. Biomaterials. 2012;33:5574-5583.
5. Mylonakis N, Athanasiou A, Ziras N, et al. Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer. 2010;68:240-247.
6. Lin YJ, Liu YS, Yeh HH, Cheng TL, Wang LF. Self-assembled poly(epsilon-caprolactone)-g-chondroitin sulfate copolymers as an intracellular doxorubicin delivery carrier against lung cancer cells. Int J Nanomedicine. 2012;7:4169-4183.
7. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303:1818-1822.
8. Esfandyari-Manesh M, Javanbakht M, Atyabi F, Dinarvand R. Synthesis and evaluation of uniformly sized carbamazepine-imprinted microspheres and nanospheres prepared with different mole ratios of methacrylic acid to methyl methacrylate for analytical and biomedical applications. J Appl Polym Sci. 2012;125:1804-1813.
9. Liu J, Meisner D, Kwong E, Wu XY, Johnston MR. Translymphatic chemotherapy by intrapleural placement of gelatin sponge containing biodegradable paclitaxel colloids controls lymphatic metastasis in lung cancer. Cancer Res. 2009;69:1174-1181.
10. Tien H, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol. 2012;7:1361-1368.
11. Videira M, Almeida AJ. Preclinical evaluation of a pulmonary delivered paclitaxel-loaded lipid nanocarrier antitumor effect. Nanomedicine. 2012;8:1208-1215.
12. Yang R, Shim WS, Cui FD, et al. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int J Pharm. 2009;37:142-147.
13. 2k) micelles for targeted and synergistic chemotherapy. Biomaterials. 2011;32:4058-4066.
14. Mei L, Sun H, Song C. Local delivery of modified paclitaxel-loaded poly(epsilon-caprolactone)/pluronic F68 nanoparticles for long-term inhibition of hyperplasia. J Pharm Sci. 2009;98:2040-2050.
15. Yang R, Yan SG, Shim WS, et al. Lung-specific delivery of paclitaxel by chitosan-modified PLGA nanoparticles via transient formation of microaggregates. J Pharm Sci. 2008;98:970-984.
16. Fan L, Wu H, Zhang H, Li F, Yang TH. pH-sensitive podophyllotoxin carrier for cancer cells specific delivery. Polym Compos. 2010;31: 51-59.
17. Thamake SI, Raut SL, Gryczynski Z, Ranjan AP, Vishwanatha JK. Alendronate coated poly-lactic-co-glycolic acid (PLGA) nanoparticles for active targeting of metastatic breast cancer. Biomaterials. 2012;33:7164-7173.
18. Sarbari A, Sanjeeb KS. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev. 2011;63:170-183.
19. Esfandyari-Manesh M, Javanbakht M, Atyabi F, Badiei A, Dinarvand R. Effect of porogenic solvent on the morphology, recognition and release properties of carbamazepine molecularly imprinted polymer nanospheres. J Appl Polym Sci. 2011;121:1118-1126.
20. Sanna V, Roggio AM, Posadino AM, et al. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactideco-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett. 2011;6:260.
21. Zeng XW, Chen HB, Zheng Y, et al. Enhanced adsorption of puerarin onto a novel hydrophilic and polar modified post-crosslinked resin from aqueous solution. J Colloid Interface Sci. 2012;385:166-173.
22. Wang H, Zhao Y, Wu, et al. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials. 2011;32:8281-8290.
23. Esfandyari-Manesh M, Javanbakht M, Dinarvand R, Atyabi F. Molecularly imprinted nanoparticles prepared by miniemulsion polymerization as selective receptors and new carriers for the sustained release of carbamazepine. J Mater Sci Mater Med. 2012;23: 963-972.
24. Danhier F, Ansorena E, Silva JM, Coco R, Breton AL, Préat V. PLGAbased nanoparticles: an overview of biomedical applications. J Control Release. 2012;161:505-522.
25. Wu Z, Ling L, Zhou L, et al. Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery. Nanoscale Res Lett. 2012;7:299.
26. Ma YD, Zheng Y, Zeng XW, et al. Novel docetaxel-loaded nanoparticles based on PCL-Tween 80 copolymer for cancer treatment. Int J Nanomedicine. 2011;6:2679-2688.
27. Vert M. Degradable and bioresorbable polymers in surgery and in pharmacology: beliefs and facts. J Mater Sci Mater Med. 2009;20: 437-446.
28. Sun H, Mei L, Song C, Cui X, Wang P. The in vivo degradation, absorption and excretion of PCL-based implant. Biomaterials. 2006;27: 1735-1740.
29. Zhou S, Xu J, Yang H, Deng X. Synthesis and characterization of biodegradable poly(ε-caprolactone)-polyglycolide-poly(ethylene glycol) monomethyl ether random copolymer. Macromol Mater Eng. 2004;289: 576-580.
30. Tsai YM, Chang-Liao WL, Chien CF, Lin LC, Tsai TH. Effects of polymer molecular weight on relative oral bioavailability of curcumin. Int J Nanomedicine. 2012;7:2957-2966.
31. Fox ME, Szoka FC, Fréchet AMJ. Soluble polymer carriers for the treatment of cancer: the importance of molecular architecture. Acc Chem Res. 2009;42:1141-1151.
32. Lu T, Jing X, Song X, Wang X. Doxorubicin-loaded ultrafine PEG- PLA fiber mats against hepatocarcinoma. J Appl Polym Sci. 2012;123: 209-217.
33. Rojnik M, Kocbek P, Moret F, et al. In vitro and in vivo characterization of temoporfin-loaded PEGylated PLGA nanoparticles for use in photodynamic therapy. Nanomedicine. 2012;7:663-677.
34. Huang LQ, Chen HB, Zheng Y, et al. Nanoformulation of D-atocopheryl polyethylene glycol 1000 succinate-b-poly (ε-caprolactoneran-glycolide) diblock copolymer for breast cancer therapy. Integr Biol (Camb). 2011;3:993-1002.
35. Youk HJ, Lee E, Choi MK, et al. Enhanced anticancer efficacy of alphatocopheryl succinate by conjugation with polyethylene glycol. J Control Release. 2005;107:43-52.
36. Tian HY, Tang ZH, Zhuang XL, Chen XS, Jing XB. Biodegradable synthetic polymers: preparation, functionalization and biomedical application. Prog Polym Sci. 2012;37:237-280.
37. Mei L, Zhang Y, Zheng Y, et al. A novel docetaxel-loaded poly(εcaprolactone)/pluronic F68 nanoparticle overcoming multidrug resistance for breast cancer treatment. Nanoscale Res Lett. 2009;4: 1530-1539.
38. Ma YD, Huang LQ, Song C., Zeng XW, Gan L, Mei L. Nanoparticle formulation of poly(ε-caprolactone-co-lactide)-d-α-tocopheryl polyethylene glycol 1000 succinate random copolymer for cervical cancer treatment. Polymer. 2010;51:5952-5959.
39. Zhang C, Wang W, Liu T, et al. Doxorubicin-loaded glycyrrhetinic acid-modified alginate nanoparticles for liver tumor chemotherapy. Biomaterials. 2012;33:2187-2196.
40. Guo JW, Gao XL, Su LN, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32:8010-8020.
41. Ouyang CP, Ma GL, Zhao SX, et al. Preparation and characterization of the molecular weight controllable poly(lactide-co-glycolide). Polym Bull. 2011;67:793-803.
42. Sanna V, Sechi M. Nanoparticle therapeutics for prostate cancer treatment. Nanomedicine. 2012;8:S31-S36.
43. Yan F, Zhang C, Zheng Y, et al. The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity. Nanomedicine. 2010;6:170-178.
44. Liu YT, Li K, Liu B, Feng SS. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials. 2010;31:9145-9155.
45. Chen H, Zheng Y, Tian G, et al. Oral delivery of DMAB-modified docetaxel-loaded PLGA-TPGS nanoparticles for cancer chemotherapy. Nanoscale Res Lett. 2011;6:4.
46. Xiao K, Li Y, Luo J, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32:3435-3446.
47. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent evaporation/extraction technique for fabrication of polymeric nanospheres for controlled release of paclitaxel (Taxol). J Control Release. 2002;80:129-144.
48. Ma Y, Zheng Y, Liu K, et al. Nanoparticles of poly(lactide-co-glycolide)-D-a-tocopheryl polyethylene glycol 1000 succinate random copolymer for cancer treatment. Nanoscale Res Lett. 2010;5:1161-1169.
49. Feng SS, Mei L, Anitha P, Gan CW, Zhou WY. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of docetaxel. Biomaterials. 2009;30:3297-3306.